Glyxambi (empagliflozin and linagliptin) is a tablet that is taken orally in patients with type 2 diabetes mellitus to improve their blood sugar control. It is used in conjunction with diet and exercise.
HOW DOES GLYXAMBI WORK?
Glyxambi is a combination tablet. It contains empagliflozin, a sodium-glucose co-transporter (SGLT2) inhibitor and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Empagliflozin reduces the amount of glucose that is reabsorbed from the kidneys and so lowers blood glucose concentrations in the blood. Linagliptin prevents the breakdown of incretin hormones. Incretin hormones increase the secretion of insulin and decrease the concentration of glucagon. By inhibiting the breakdown of incretin, there is a reduction in blood glucose levels in the blood.
WHAT ARE THE INDICATIONS FOR GLYXAMBI?
Glyxambi is indicated for the management of patients with type 2 diabetes mellitus. It is used in combination with diet and exercise to improve blood glucose concentrations.
WHAT IS THE DOSE OF GLYXAMBI?
The dose of Glyxambi is given as a 10/5 mg combination tablet. This contains 10 mg empagliflozin and 5 mg linagliptin and is taken once daily in the morning. If this dose is well-tolerated, it can be increased to a 25/5 mg combination tablet. This contains 25 mg empagliflozin and 5 mg linagliptin and is taken once daily in the morning.